Magrolimab (Hu5F9-G4)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Magrolimab (Hu5F9-G4), covering 2024-04-01 to 2025-05-29. Get the full timeline:
Most recent: Clinical Trial Update: Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]